We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
IL-4 and TNF-α Polymorphisms Are Associated with Risk of Multiple Superficial Tumors or Carcinoma in situ Development.
- Authors
Lima, Luís; Silva, Joana; Amaro, Teresina; Morais, António; Lopes, Carlos; Medeiros, Rui; Videira, Paula A.; Santos, Lúcio
- Abstract
Introduction: This study evaluates the influence of clinicopathological characteristics, bacillus Calmette-Guérin (BCG) therapeutic schedule [maintenance (mBCG) or induction (iBCG)], and TNF-α and IL-4 polymorphisms on the outcome of non-muscle-invasive bladder cancer patients treated with BCG. Material and Methods: DNA was extracted from 125 bladder cancer patients treated with BCG; TNF-308G/A and IL4-590C/T polymorphisms were genotyped. Results: The TNF-308A allele carriers had an increased risk of developing multiple tumors (OR: 2.80, p = 0.031). However, IL4-590 T carriers also had an increased risk of developing multiple and carcinoma in situ tumors (OR: 2.52, p = 0.033). For these polymorphisms, no association was found with BCG treatment outcome. When treated with iBCG, patients with multiple tumors had shorter recurrence-free survival (RFS) compared with those with a single tumor (p = 0.004); nevertheless, patients with multifocal tumors have improved RFS when treated with mBCG. Conclusions: Overall, the results suggest that multiple tumors and/or carcinoma in situ development are associated with the IL4-590C/T and TNF-308G/A polymorphisms, and emphasize the effectiveness of the mBCG schedule. Copyright © 2011 S. Karger AG, Basel
- Subjects
TUMOR necrosis factors; GENETIC polymorphisms; CANCER treatment; BCG vaccines; INTERLEUKIN-4; BLADDER cancer treatment; HEALTH outcome assessment
- Publication
Urologia Internationalis, 2011, Vol 87, Issue 4, p457
- ISSN
0042-1138
- Publication type
Article
- DOI
10.1159/000331882